These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 38673836)

  • 1. Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA.
    Frydendahl A; Rasmussen MH; Jensen SØ; Henriksen TV; Demuth C; Diekema M; Ditzel HJ; Wen SWC; Pedersen JS; Dyrskjøt L; Andersen CL
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond basics: Key mutation selection features for successful tumor-informed ctDNA detection.
    Nesic M; Rasmussen MH; Henriksen TV; Demuth C; Frydendahl A; Nordentoft I; Dyrskjøt L; Andersen CL
    Int J Cancer; 2024 Sep; 155(5):925-933. PubMed ID: 38623608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for improving detection of circulating tumor DNA using next generation sequencing.
    Tébar-Martínez R; Martín-Arana J; Gimeno-Valiente F; Tarazona N; Rentero-Garrido P; Cervantes A
    Cancer Treat Rev; 2023 Sep; 119():102595. PubMed ID: 37390697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations.
    Theparee T; Akroush M; Sabatini LM; Wang V; Mangold KA; Joseph N; Stocker SJ; Freedman A; Helseth DL; Talamonti MS; Kaul KL
    Sci Rep; 2024 Jul; 14(1):15744. PubMed ID: 38977725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.
    Quivoron C; Michot JM; Danu A; Lecourt H; Saada V; Saleh K; Vergé V; Cotteret S; Bernard OA; Ribrag V
    Leuk Lymphoma; 2024 Jun; 65(6):789-799. PubMed ID: 38433500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
    Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
    J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the biology of ctDNA release in colorectal cancer.
    Andersen L; Kisistók J; Henriksen TV; Bramsen JB; Reinert T; Øgaard N; Mattesen TB; Birkbak NJ; Andersen CL
    Eur J Cancer; 2024 Aug; 207():114186. PubMed ID: 38943900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer.
    Santonja A; Cooper WN; Eldridge MD; Edwards PAW; Morris JA; Edwards AR; Zhao H; Heider K; Couturier DL; Vijayaraghavan A; Mennea P; Ditter EJ; Smith CG; Boursnell C; Manzano García R; Rueda OM; Beddowes E; Biggs H; Sammut SJ; Rosenfeld N; Caldas C; Abraham JE; Gale D
    EMBO Mol Med; 2023 Jun; 15(6):e16505. PubMed ID: 37161793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection and stratification of colorectal cancer using plasma cell-free DNA fragmentomic profiling.
    Zhou J; Pan Y; Wang S; Wang G; Gu C; Zhu J; Tan Z; Wu Q; He W; Lin X; Xu S; Yuan K; Zheng Z; Gong X; JiangHe C; Han Z; Huang B; Ruan R; Feng M; Cui P; Yang H
    Genomics; 2024 Jul; 116(4):110876. PubMed ID: 38849019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.
    Harter J; Buth E; Johaenning J; Battke F; Kopp M; Zelba H; Schulze M; Koedding J; Biskup S
    J Mol Diagn; 2024 Jan; 26(1):61-72. PubMed ID: 37865292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
    Widman AJ; Shah M; Frydendahl A; Halmos D; Khamnei CC; Øgaard N; Rajagopalan S; Arora A; Deshpande A; Hooper WF; Quentin J; Bass J; Zhang M; Langanay T; Andersen L; Steinsnyder Z; Liao W; Rasmussen MH; Henriksen TV; Jensen SØ; Nors J; Therkildsen C; Sotelo J; Brand R; Schiffman JS; Shah RH; Cheng AP; Maher C; Spain L; Krause K; Frederick DT; den Brok W; Lohrisch C; Shenkier T; Simmons C; Villa D; Mungall AJ; Moore R; Zaikova E; Cerda V; Kong E; Lai D; Malbari MS; Marton M; Manaa D; Winterkorn L; Gelmon K; Callahan MK; Boland G; Potenski C; Wolchok JD; Saxena A; Turajlic S; Imielinski M; Berger MF; Aparicio S; Altorki NK; Postow MA; Robine N; Andersen CL; Landau DA
    Nat Med; 2024 Jun; 30(6):1655-1666. PubMed ID: 38877116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer.
    Yu P; Chen P; Wu M; Ding G; Bao H; Du Y; Xu Z; Yang L; Fang J; Huang X; Lai Q; Wei J; Yan J; Yang S; He P; Wu X; Shao Y; Su D; Cheng X
    Genome Med; 2024 Jun; 16(1):79. PubMed ID: 38849905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep learning model integrating cfDNA methylation and fragment size profiles for lung cancer diagnosis.
    Kim M; Park J; Seonghee Oh ; Jeong BH; Byun Y; Shin SH; Im Y; Cho JH; Cho EH
    Sci Rep; 2024 Jun; 14(1):14797. PubMed ID: 38926407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.
    Nakano T; Takao S; Dairaku K; Uno N; Low SA; Hashimoto M; Tsuda Y; Hisamatsu Y; Toshima T; Yonemura Y; Masuda T; Eto K; Ikegami T; Fukunaga Y; Niida A; Nagayama S; Mimori K
    Cancer Sci; 2024 Jun; 115(6):1989-2001. PubMed ID: 38531808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.
    Northcott J; Bartha G; Harris J; Li C; Navarro FCP; Pyke RM; Hong M; Zhang Q; Ma S; Chen TX; Lai J; Udar N; Saldivar JS; Ayash E; Anderson J; Li J; Cui T; Le T; Chow R; Velasco RJ; Mallo C; Santiago R; Bruce RC; Goodman LJ; Chen Y; Norton D; Chen RO; Lyle JM
    Oncotarget; 2024 Jun; 15():407. PubMed ID: 38900651
    [No Abstract]   [Full Text] [Related]  

  • 16. A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice.
    Kramer A; Schuuring E; Vessies DCL; van der Leest P; Geerlings MJ; Rozendal P; Lanfermeijer M; Linders TC; van Kempen LC; Fijneman RJA; Ligtenberg MJL; Meijer GA; van den Broek D; Retèl VP; Coup VMH;
    J Mol Diagn; 2023 Jan; 25(1):36-45. PubMed ID: 36402278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing nullomers in cell-free RNA for early cancer detection.
    Montgomery A; Tsiatsianis GC; Mouratidis I; Chan CSY; Athanasiou M; Papanastasiou AD; Kantere V; Syrigos N; Vathiotis I; Syrigos K; Yee NS; Georgakopoulos-Soares I
    Cancer Gene Ther; 2024 Jun; 31(6):861-870. PubMed ID: 38351138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROMER technology: A new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity.
    Nam H; Lee E; Yang H; Lee K; Kwak T; Kim D; Kim H; Yang M; Yang Y; Son S; Nam YH; Minn I
    Biol Methods Protoc; 2024; 9(1):bpae041. PubMed ID: 38938409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On statistical modeling of sequencing noise in high depth data to assess tumor evolution.
    Rabadan R; Bhanot G; Marsilio S; Chiorazzi N; Pasqualucci L; Khiabanian H
    J Stat Phys; 2018 Jul; 172(1):143-155. PubMed ID: 30034030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
    Brown JR; Sonpavde GP; Calaway A; Barata PC
    Eur Urol; 2024 Jun; ():. PubMed ID: 38880696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.